Program
BMS-986521
A development code.
Its studies are led by Bristol-Myers Squibb.
Furthest: phase 1, since May 29, 20261 company-led study, 1 open or runningNext primary completion: Dec 27, 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 11 open or running | phase 1since May 29, 2026 | May 29, 2026 | Dec 27, 2026phase 1 · NCT07655518 |
- Named in Bristol-Myers Squibb’s own pipeline as
BMS-986521
, phase 1, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 29, 2026First study: phase 1 study in Healthy VolunteersFirst studyNCT07655518 · 12 planned · Belgium
Ahead
- Dec 27, 2026Primary completion: phase 1 study in Healthy VolunteersNCT07655518
TargetBeta
“A Phase 1, Open-label, Positron Emission Tomography (PET) Imaging Study to Evaluate M4 Muscarinic Acetylcholine Receptor Occupancy in the Central Nervous System Using [11C]MK-6884 PET Tracer Before and After Oral Administration of Multiple Doses of BMS-986521 in Healthy Adult Participants”study text, read by Claude · the study
Other programs on CHRM4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Glycopyrrolaterule | Novartis | phase 4 | 87 |
| xanomelinerule | Bristol-Myers Squibb | phase 4 | 38 |
| emraclidine | AbbVie | phase 2 | 18 |
| GXV-813 | Novartis | phase 2 | 1 |
| ABBV-1042 | AbbVie | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07655518Healthy Volunteers · Belgium | 1 | Recruiting | Dec 27, 2026 | 12 |
How it is read
Names in the registry
- “BMS-986521”, 1 entry
Codes read as this program: BMS986521.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.